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ABSTRACT
Objective The sensitivity and specificity of a single faecal
immunochemical test (FIT) are limited. The performance
of FIT screening can be improved by increasing the
screening frequency or by providing more than one
sample in each screening round. This study aimed to
evaluate if two-sample FIT screening is cost-effective
compared with one-sample FIT.
Design The MISCANecolon microsimulation model was
used to estimate costs and benefits of strategies with
either one or two-sample FIT screening. The FIT cut-off
level varied between 50 and 200 ng haemoglobin/ml,
and the screening schedule was varied with respect to
age range and interval. In addition, different definitions
for positivity of the two-sample FIT were considered: at
least one positive sample, two positive samples, or the
mean of both samples being positive.
Results Within an exemplary screening strategy,
biennial FIT from the age of 55e75 years, one-sample
FIT provided 76.0e97.0 life-years gained (LYG) per 1000
individuals, at a cost of V259 000e264 000 (range
reflects different FIT cut-off levels). Two-sample FIT
screening with at least one sample being positive
provided 7.3e12.4 additional LYG compared with
one-sample FIT at an extra cost of V50 000e59 000.
However, when all screening intervals and age ranges
were considered, intensifying screening with one-sample
FIT provided equal or more LYG at lower costs compared
with two-sample FIT.
Conclusion If attendance to screening does not differ
between strategies it is recommended to increase the
number of screening rounds with one-sample FIT
screening, before considering increasing the number of
FIT samples provided per screening round.
In industrialised countries colorectal cancer (CRC)
is the third most commonly diagnosed malignancy
in men and ranks second in women.1 The majority
of CRC cases are diagnosed later in life. Because life
expectancy increases in many countries and the
costs of CRC treatment rise rapidly, it is expected
that CRC will place an increasing burden on
national healthcare systems.
Screening for CRC and its premalignant lesions
(ie, adenomatous polyps) can detect the disease at
an earlier and more curable stage. Faecal occult
blood tests (FOBT) have been developed to detect
microscopic bleeding from colorectal neoplasms
before there are any clinical signs or symptoms. At
least three randomised controlled trials have proved
the effectiveness FOBT screening, demonstrating
a mortality reduction of 15e33%.2e4 Subsequently,
several screening trials have confirmed the superi-
ority of faecal immunochemical test (FIT)
screening over the more traditionally used guaiac-
based FOBT (ie, non-rehydrated Hemoccult-II test)
both with respect to attendance as well as the
detection rate of advanced neoplasia.5e11 Most of
these trials used screening strategies with a single
FIT sample.
As not all advanced neoplasia will be detected
by means of one-sample FIT screening, providing
two FIT samples collected on consecutive days
could increase the effectiveness of a screening
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Significance of this study
What is already known on this subject?
< Two-sample FIT screening with referral for
colonoscopy if at least one sample is positive
provides a higher detection rate for advanced
neoplasia than one-sample FIT screening.
< However, this is at the expense of higher
positivity rates and thus the need for more
colonoscopies.
What are the new findings?
< Within a given screening age range and interval,
two-sample FIT screening provides additional
LYG compared with one-sample FIT screening at
acceptable costs.
< Intensifying screening with one-sample FIT
provides equal or more LYG at lower costs,
compared with screening by means of two-
sample FIT.
How might it impact on clinical practice in the
foreseeable future?
< In order to improve the effectiveness of their
CRC screening programme, decision-makers are
recommended to increase the number of
screening rounds with one-sample FIT
screening, before considering increasing the
number of FIT samples provided per screening
round.
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programme. On the one hand, referring a screenee for a diag-
nostic colonoscopy when at least one sample is positive
increases sensitivity because some colorectal neoplasms bleed
intermittently and can therefore be missed with one-sample FIT
screening.12 On the other hand, referring a screenee when both
samples are positive can increase specificity because only colonic
lesions with a more consistent bleeding pattern will be detected,
which will lead to fewer false-positive test results. However,
either way, providing two FIT samples within one screening
round will also increase screening costs because twice the
number of samples need to be analysed.
The aim of this study was to evaluate the cost-effectiveness of
one-sample and two-sample FIT screening strategies with vari-
able intervals, age ranges and cut-off levels in order to assess
whether the increased performance of a second FIT sample
outweighs the increased costs compared with one-sample FIT
screening.
MATERIALS AND METHODS
We used the MISCANecolon microsimulation model to
estimate the additional life-years gained (LYG) and costs of
two-sample FIT screening over one-sample FIT for the screening
strategy of biennial FIT from the age 55 to 75 years. This
screening strategy has intermediate screening intensity and
was previously found to be cost-effective.13 Additional LYG
can also be achieved by increasing the intensity of one-sample
FIT screening instead of adding a second sample. We therefore
also compared the costs and LYG of one-sample FIT
screening with that of two-sample FIT for a range of screening
strategies.
MISCANecolon microsimulation model
The MISCANecolon model and the data sources that inform
the quantifications of the model are described in detail in
supplementary appendix 1, in previous publications,14e18 and in
a standardised model profile available online only.19 In brief, the
MISCANecolon model simulates the relevant life histories of
a large population of individuals from birth to death. CRC arises
in this population according to the adenomaecarcinoma
sequence.20 21 More than one adenoma can occur in an indi-
vidual and each adenoma can independently develop into
a CRC. Adenomas progress in size from small (#5 mm) to
medium (6e9 mm) to large ($10 mm). Although most
adenomas will never turn into cancer, some will eventually
become malignant, transforming to stage I CRC and some may
even progress into stage IV. In every stage, there is a probability
of the CRC being diagnosed due to the development of symp-
toms versus symptomless progressing into the next stage. If
CRC has developed, the survival rate after clinical diagnosis
depends on the stage in which the cancer was detected. The 5-
year survival rate is on average 90% if the disease is diagnosed
while still localised, 68% for regional disease, and less than 10%
for disseminated disease. At any time during the development of
the disease, the process may be interrupted because a person dies
of other causes.
With FIT screening lesions can be detected before clinical
diagnosis; a screened individual with a positive test result will be
referred for a colonoscopy for the detection and removal of
adenomas and early-stage cancers. In this way, CRC incidence
and/or CRC-related mortality can be reduced. The LYG by
screening are calculated as the difference in model-predicted
life years lived in the population with and without CRC
screening.
Study population
In this study we modelled the age distribution of the Dutch
population in 200522 and all individuals were followed until
death. The CRC incidence rate was based on the observed
incidence rate in The Netherlands in 1999e2003, which was
before the onset of opportunistic screening.23 The observed
CRC incidence in the population included cases from higher
risk groups. Survival rates after clinical diagnosis of CRC was
based on relative survival data from 1985 to 2004 from the
south of The Netherlands,24 since nationwide data were not
available. The survival for individuals aged 75 years and older
was adjusted to fit the observed age-increasing mortality/inci-
dence ratio.23
Screening strategies
CRC screening was simulated in the population starting in 2010.
Individuals were offered FIT screening according to different
screening schedules varying by:
Age to start screening at, respectively, 45, 50, 55 and 60 years
Age to stop screening at, respectively, 70, 75 and 80 years
Screening interval with, respectively, 1, 1.5, 2 and 3 years
Separate simulations were performed in which individuals
were invited for: one-sample FIT screening; two-sample
FIT screening with referral if at least one sample tested
positive; two-sample FIT screening with referral only if both
samples tested positive; or two-sample FIT screening with
referral if the mean of both samples was positive. The cut-off
level for a positive test result varied between 50, 75, 100, 150
and 200 ng haemoglobin/ml. These different screening
schedules with varying start and stop ages, intervals, cut-off
levels and samples resulted in a total of 960 different screening
strategies.
After a positive test result, individuals were referred for
colonoscopy. If no adenomas were found during the procedure,
the individual was assumed to be at low risk of CRC and did not
return to the screening programme until after 10 years. If one or
more adenomas were found, they were removed and the indi-
vidual entered a surveillance programme according to the Dutch
guidelines for follow-up after polypectomy,25 ie, a colonoscopy
after 6 years in the case of one or two adenomas and after
3 years in the case of three or more adenomas. We assumed that
surveillance colonoscopies would be performed until the stop
age for screening.
Attendance rates
We modelled attendance rates in the first screening round
as observed in two Dutch population-based CRC screening
trials;9 11 12 60% for both one and two-sample FITscreening, and
we assumed these rates would remain stable over time. For
subsequent screening rounds, we assumed that 80% of the
individuals who attended the previous screening round would
attend again.26 27 Furthermore, we assumed that 10% of the
individuals never attended FIT screening28 and that these never-
attenders had a higher risk of CRC than the general population
(RR 1.15).2 Attendance at diagnostic colonoscopies following
a positive FIT and subsequent surveillance colonoscopies were
assumed to be 85% and 80%, respectively.29
Test characteristics
Test characteristics of the one-sample and two-sample FIT tests
were fitted to the positivity rates and detection rates of
advanced neoplasia observed in the first screening round of two
Dutch randomised trials (table 1).9e12 Advanced neoplasia
included CRC and advanced adenomas, of which the latter was
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defined as adenomas of 10 mm or greater in size, with 25% or
greater villous component, and/or high-grade dysplasia.
To estimate the two-sample FIT test characteristics the
following approach was applied; we used the average positivity
rates and detection rates of the first and second test performed
from the two-sample FIT group as reference and calculated the
relative difference in performance when both samples were
evaluated. Subsequently, we added this relative difference to the
positivity rates and detection rates derived from the original one-
sample FIT trials. An example of this method of calculation is
presented in figure 1. The main reasons for this approach were:
(1) the larger sample size of the one-sample FIT group provides
more statistical power for the estimates of test sensitivity and
specificity; (2) to avoid possible bias caused by the fact that the
positivity rates and detection rates of the one-sample and two-
sample FIT groups were calculated from different cohorts that
were not 1:1 randomly assigned before invitation;10 12 (3) in this
way we used paired observations, which gives a better estimate
of the additional performance of a second FIT sample.
The sensitivity of diagnostic colonoscopies was assumed to be
75% for adenomas 1e5 mm, 85% for adenomas 6e9 mm, and
95% for adenomas 10 mm or greater and CRC.30
Costs
The analysis was conducted from a healthcare system perspec-
tive. In the base case analyses, we included screening and
treatment costs as presented in table 2. Base case organisational
costs for one-sample FIT screening were based on the Dutch
cervical cancer screening programme, adjusted for differences
with FIT screening. Costs for the test kits were based on prices
from the manufacturer. Costs for analysis of the tests included
material and personnel needed during the process of registration,
analysis and authorisation of returned tests.34 The additional
costs associated with two-sample FIT screening included double
costs for FIT test kits and packaging material, and double costs
for materials needed during the analysis of returned samples.
Although double the number of FIT samples would need to be
analysed, the costs of personnel needed for the analysis only
increased by a factor of 1.5 because some tasks (eg, patient
registration) do not require double the amount of work
compared with analysing samples with one-sample FIT
screening. Colonoscopy costs were based on an internal
6 months study at the Erasmus MC (data not shown). Costs for
complications after colonoscopy were based on diagnosis treat-
ment combination (DTC) rates derived from the Dutch Health
Care Authority.35
Costs for treatment of CRC were divided into three clinically
relevant phases of care: initial treatment, continuous care and
terminal care. Initial treatment costs were based on DTC rates,
except for oxaliplatin. The costs for oxaliplatin were derived from
the Dutch Health Care Insurance Board.36 We assumed that
during the continuous care phase, individuals would follow the
Dutch CRC treatment guidelines,37 and costs for periodic control
were based on DTC rates. Terminal care costs were based on
a Dutch last year of life cost analysis. These were estimated at
V19 700 for patients who ultimately died from CRC.38 We
assumed that these costs increased with stage at diagnosis, at
a rate observed for US patients.39 40 Dutch terminal care costs for
Table 1 Test characteristics of one-sample and two-sample FIT used in the model
Cut-off level (ng Hb/ml)
Specificity
(per person, %)
Sensitivity (per lesion, %)*
Adenoma
CRC early preclinicaly CRC late preclinicaly£5 mm 6e9 mm ‡10 mm
One-sample FIT
50 95.79 0.0 9.6 16.1 65.0 90.0
75 97.05 0.0 5.7 14.4 58.5 87.0
100 97.76 0.0 4.4 13.1 52.0 83.5
150 98.34 0.0 2.9 12.3 50.5 83.0
200 98.70 0.0 2.5 10.3 50.0 82.5
Two-sample FIT, at least one sample positive
50 93.01 0.0 14.2 16.7 75.0 93.5
75 94.90 0.0 8.4 15.5 71.0 92.0
100 96.03 0.0 6.9 14.4 66.0 90.0
150 97.03 0.0 5.2 14.3 66.0 90.0
200 97.65 0.0 4.9 12.5 66.0 90.0
Two-sample FIT, mean of both samples positive
50 95.51 0.0 12.6 17.0 67.0 90.0
75 96.90 0.0 7.5 15.1 61.0 87.5
100 97.66 0.0 5.4 13.8 54.0 84.0
150 98.31 0.0 3.3 12.8 51.0 83.0
200 98.63 0.0 2.1 10.7 49.0 81.5
Two-sample FIT, both samples positive
50 98.40 0.0 3.8 12.0 34.0 70.0
75 98.94 0.0 1.8 10.0 29.0 65.0
100 99.21 0.0 0.9 8.8 24.0 59.0
150 99.43 0.0 0.1 7.1 20.0 53.0
200 99.49 0.0 0.0 5.2 16.0 47.5
The test characteristics used in the model were fitted to the positivity rates and detection rates of advanced neoplasia and CRC from two Dutch randomised controlled trials.9e12 Sensitivity for
adenomas smaller than 5 mm was assumed to be 0% for all tests, at any cut-off level.
*Excluding the probability that an adenoma or cancer is found due to a lack of specificity.
yIt was assumed that the probability a CRC bleeds and thus the sensitivity of FIT for CRC depends on the time until clinical diagnosis, in concordance with findings for FOBT, which were based
on a previous calibration of the MISCANecolon model to three FOBT trials.16 This result is to be expected when cancers that bleed do so increasingly over time, starting ‘occultly’ and ending as
clinically visible. This interpretation also holds for FIT.
CRC, colorectal cancer; FIT, faecal immunochemical test; FOBT, faecal occult blood tests; Hb, haemoglobin.
Colon
Gut 2013;62:727–734. doi:10.1136/gutjnl-2011-301917 729
group.bmj.com on July 13, 2017 - Published by http://gut.bmj.com/Downloaded from 
individuals who died from CRC were approximately 40% of the
US costs. We assumed that terminal care costs of CRC patients
who die from other causes were also 40% of the US costs.
Cost-effectiveness analyses
For all screening strategies we used the MISCANecolon model
to estimate costs and compare the number of LYG due to
screening with the situation without screening. Costs and LYG
were discounted by 3% per year.41 Strategies that were more
costly and less effective than other strategies were ruled out by
simple dominance. Strategies that were more costly and less
effective than a mix of other strategies were ruled out by
extended dominance. The remaining strategies are not domi-
nated and are known as ‘efficient’. On a plot of LYG versus costs,
the line that connects the efficient strategies is called the effi-
cient frontier, which implies that all dominated strategies lie
below this line. The incremental cost-effectiveness ratio (ICER)
of an efficient strategy was determined by comparing its addi-
tional costs and effects with those of the next less costly and less
effective efficient strategy.
Sensitivity analyses
We performed several sensitivity analyses on different parame-
ters, which are summarised in table 2. We started with
sensitivity analyses with respect to the additional performance
and costs of two-sample FIT over one-sample FIT. Furthermore,
we adjusted for reduced quality of life due to screening as well as
CRC treatment. Correlated FIT test results were assumed
because individuals with a false-negative test result are likely to
have a higher than average probability to have another false-
negative test result at a successive screening round. We used the
results of a population-based CRC screening programme in Italy
to estimate the correlation between false-negative FITresults for
cancers and advanced adenomas in subsequent screening
rounds.33 Effects of limited colonoscopy capacity were evaluated
by only considering strategies in which colonoscopy demand did
not exceed 40, 20, 10, or five colonoscopies per 1000 individuals
per year. In order to assess the cost-effectiveness of the different
strategies for individuals who adhere to the CRC screening
guidelines, we simulated all screening strategies with 100%
attendance to screening, diagnostic and surveillance colonos-
copies. In addition, we performed sensitivity analyses on lower
and higher values than the base case analysis for fatal compli-
cation rates with colonoscopy and for unit costs of FIT, colo-
noscopy, complications and treatment. We decided not to
perform a probabilistic sensitivity analysis after having weighed
the limited added value against the computational effort
required (see Discussion).
RESULTS
The strategy of biennial one-sample FITscreening from age 55 to
75 years yielded 76.0e97.0 LYG per 1000 individuals aged
45 years and older, compared with no screening (the range in
LYG reflects different FIT cut-off levels). The associated costs
ranged from V259 000 to V264 000 per 1000 individuals, corre-
sponding with V2690e3473 per LYG compared with no
screening (figure 2). The two-sample FIT screening strategies
with the mean of both test results being positive and at least one
test result being positive provided, respectively, between
0.3e2.6 and 7.3e12.4 more LYG than one-sample FIT
screening at additional costs of, respectively, V43 000e50 000
and V50 000e59 000 per 1000 individuals. The corresponding
ICER ranged from V16 818e31 930 and V4024e8041 per addi-
tional LYG. The two-sample FIT screening strategies with two
positive outcomes were less effective (ie, fewer LYG per 1000
individuals) and more costly than one-sample FITscreening, and
were therefore dominated from a cost-effectiveness standpoint
(see supplementary appendix 2, available online only, for
detailed results on effects and costs for the different biennial FIT
screening strategies with the age range of 55e75 years).
When all simulated screening strategies were considered (ie,
by varying not only the cut-off level, but also the screening age
range and interval), the number of LYG compared with no
screening ranged between 17.5 and 153.4 per 1000 individuals,
and costs ranged between V105 000 and V889 000 per 1000
individuals (figure 3). The LYG and costs of the strategies on the
efficient frontier are presented in table 3. Although the ICER of
biennial two-sample FIT screening between ages 55 and 75 years
(mean of both samples being positive, or at least one sample
being positive) compared with one-sample FIT seemed reason-
able, table 3 shows that most two-sample FIT strategies are not
cost-effective. When comparing the additional effect of
providing two samples per screening round to the effect of
providing one-sample FIT more frequently (ie, with a larger age
range and/or shorter interval), the latter provided more LYG at
equal or less costs than the two-sample FIT strategies. This
effect is also demonstrated in figure 2, because the strategies of
biennial two-sample FIT are located below the efficient frontier.
Figure 1 Example of calculation of the added performance of two-
sample faecal immunochemical tests (FIT) compared with one-sample
FIT screening. *This example provides the calculation of the positivity
rate of two-sample FIT with at least one sample positive at a cut-off level
of 50 ng haemoglobin/ml. The method of calculation is similar for both
the positivity rate and detection rate, as well as for the different two-
sample FIT positivity criteria (ie, at least one sample positive, both
samples positive and the mean of both samples positive).
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The two-sample FIT screening strategies with the mean from
both test results being positive or at least one positive test
outcome were therefore ruled out by extended dominance and
were considered not to be cost-effective compared with one-
sample FITscreening. Although figure 2 demonstrates this effect
for biennial FIT screening, the principle applies to all screening
intervals, including annual screening.
Sensitivity analyses
The higher cost-effectiveness of more frequent one-sample FIT
screening compared with two-sample FIT strategies was robust
to alterations in our model assumptions. However, decreasing
the cost difference between one-sample and two-sample FIT by
50% resulted in multiple two-sample FIT strategies becoming
efficient next to one-sample FIT. In addition, limited colono-
scopy capacity did not affect the preference of one-sample FIT
over two-sample FIT strategies, with the exception of the most
stringent scenario. In case the colonoscopy demand was not
allowed to exceed five colonoscopies per 1000 individuals per
year, two-sample FITstrategies with both samples being positive
were preferred over one-sample FIT.
DISCUSSION
Our analysis demonstrates that given a screening schedule (ie,
age range and screening interval), two-sample FIT strategies
with the mean from both test results being positive or at least
one positive test outcome provide more LYG at acceptable costs
than one-sample FIT screening. However, when all simulated
screening strategies are considered (ie, including varying age
ranges and screening intervals), increasing the screening inten-
sity of one-sample FIT testing (ie, greater age range and/or
shorter screening interval) is more cost-effective than providing
two FITwithin one screening round.
Table 2 Summary of model assumptions of the base case and sensitivity analyses
sylanaesacesaBelbairaV sesylanaytivitisneSsi
Quality of life loss
 Colonoscopy  ypocsonolocreptsolyad1–
 CRC from diagnosis onwards†  (1-
utility) 
t31:nemtaertlaitinI–
 - Stage I:   0.26 during first year 
 - Stage II:  0.3   during first year 
 - Stage III: 0.4   during first year 
 - Stage IV: 0.75 during first year 
Continuous care32: 0.15 in years between initial and terminal 
phase 
Terminal care death by CRC: 0.75 in last year before dying of CRC 
Terminal care death by other cause: 0.35 in last year before dying 
of other causes
Adherence to: 
 - Screening tests  
 - Diagnostic tests 




100% adherence to all tests. 
Correlation of FOBT results (samonedaegralehtfo%47– ≥10 mm) that are not detected, will 








- 1 per 10 000 colonoscopies 
without polypectomy
Relative increase in test 
performance between 1-sample 
and 2-sample FIT 
Average of the first and second sample used as comparator Relative increase in test 
performance 50% smaller  
Relative increase in test 
performance 50% greater 
FIT costs TIFelpmas-2TIFelpmas-1
Costs per invitation (organization 
and test kit)
67.71€15.51€
Difference between 1- and 2-
sample FIT 50% smaller 
Difference between 1- and 2-
sample FIT 200% greater 




Without polypectomy €303 %002%05
With polypectomy €393 














Stage I €12 100 €340 €17 500 €4400 %002%05
Stage II €16 600 €340 €17 500 €4000 
Stage III €20 600 €340 €18 500 €5200 
Stage IV €24 600 €340 €25 000 €14 000 
*The assumed complication rate is 2.4 per 1000 colonoscopies.
yCRC treatments were divided into three clinically relevant phasesdinitial, continuous and terminal care. The initial phase was defined as the first 12 months following diagnosis, the terminal
phase was defined as the final 12 months of life, and the continuous phase was defined as all months between the initial and terminal phase. For patients surviving less than 24 months, the final
12 months were allocated to the terminal phase. The remaining months of observation were allocated to the initial phase.
CRC, colorectal cancer; FIT, faecal immunochemical test; FOBT, faecal occult blood tests.
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This study was based on data from a randomised trial in
which the attendance and diagnostic yield of one and two-
sample FIT were compared.12 Considering only the relation
between the positivity rate and the detection rate of advanced
adenomas it seems that to choose FIT screening with either one
or two samples based on the available colonoscopy capacity
should be recommended. However, the current analysis
demonstrates that including the costs for the screening and
treatment of CRC over multiple screening rounds affects the
relation between one and two-sample FIT. Although a number
of two-sample FIT screening strategies (eg, with at least one
sample, or the mean of both samples being positive) are close to
the cost-efficiency frontier, increasing the number of one-sample
FIT screening rounds was found to be a more cost-effective way
of gaining health benefits.
Other cost-effectiveness analyses determining the optimal
number of FIT samples are limited. Two Japanese studies
compared the costs of FIT screening with either one, two or
three FIT per cancer detected in a single screening round.42 43 In
all three sampling strategies individuals were referred for
Figure 2 Costs and life-years gained
(LYG) compared with no screening per
1000 individuals in 2005 (start of the
programme) for one-sample and two-
sample faecal immunochemical test
(FIT) screening at different cut-off
values. All data points represent
biennial FIT screening from age 55 to
75 years. *Per screening test (ie, one or
two-sample FIT), the data points
represent the results at cut-off values of
50, 75, 100, 150 and 200 ng
haemoglobin/ml. For each test, a higher
cut-off level is associated with fewer
LYG, that is the data point at the bottom
represents the result at a cut-off value
of 200 ng haemoglobin/ml, whereas the
data point at the top represents the
result at a cut-off value of 50 ng
haemoglobin/ml. 1sFIT, one-sample FIT;
2sFIT(both), two-sample FIT, referral to
colonoscopy restricted to subjects with
both samples positive; 2sFIT(mean), two-sample FIT, referral to colonoscopy restricted to subjects for whom the mean of both samples is positive;
2sFIT($1), two-sample FIT, referral to colonoscopy of all subjects with at least one sample positive. The most efficient strategies, ie, those strategies
which for a given amount of costs yield the largest number of life-years saved, are connected by the efficient frontier. The screening interventions were
modelled from the year 2005, all individuals were invited for screening until they reached the end age for screening, and healthcare costs for each









































Figure 3 Costs and life years gained
(LYG) compared with no screening per
1000 individuals in 2005 (start of the
programme), for one-sample and two-
sample faecal immunochemical test
(FIT) screening at different cut-off
values. The data represent all simulated
screening strategies, which include
various sampling strategies, cut-off
levels, screening age ranges and
intervals. *The numbers of the
strategies on the efficient frontier
correspond to the cost-efficient
strategies presented in table 3. 1sFIT,
one-sample FIT; 2sFIT (both), two-
sample FIT, referral to colonoscopy
restricted to subjects with both
samples positive; 2sFIT(mean), two-
sample FIT, referral to colonoscopy
restricted to subjects for whom the
mean of both samples is positive; 2sFIT
($1), two-sample FIT, referral to colonoscopy
of all subjects with at least one sample positive. The most efficient strategies, ie, those strategies that for a given amount of costs yield the largest
number of life-years saved, are connected by the efficient frontier. Strategies with the least intensive screening schedule (ie, small age range, and long
screening interval) are located at the bottom left of the graph, whereas strategies with the most intensive screening schedule (ie, large age range and
short screening interval) are located at the top right of the graph. The screening interventions were modelled from the year 2005, all individuals were
invited for screening until they reached the end age for that particular screening strategy, and healthcare costs for each individual were calculated until
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diagnostic colonoscopy if at least one sample was positive. In
both studies it was concluded that two-sample FIT screening
with at least one test being positive would be the most desirable
strategy from a diagnostic accuracy and cost-effectiveness stand
point. A more recent French study did include multiple screening
rounds in their cost-effectiveness model and also evaluated the
effect of different cut-off levels.44 The authors concluded that
three-sample FIT screening with a cut-off level of 50 ng
haemoglobin/ml was the most cost-effective strategy to be
preferred. The results of our current analysis do agree with these
studies about the added value of multiple FIT sampling within
a given screening schedule. More than one FIT sample can
provide additional health benefits at acceptable costs. Unfortu-
nately, these studies do not provide information comparing the
added effect of multiple FIT samples per screening round with
the effect of increasing screening intensity with one-sample FIT.
Several limitations need to be acknowledged. First, we based
our analysis on data from one screening round. Therefore, we
could not estimate the correlation of test outcomes between
successive screening rounds. Individuals with a false-negative
test result (eg, because the lesion did not bleed) in one screening
round may have a higher than average probability to have
another false-negative test result at a successive screening round.
Therefore, we performed a sensitivity analysis based on Italian
results,31 in which correlation of systematic false-negative test
outcomes was assumed for advanced adenomas and CRC. The
analysis showed that the cost-effectiveness of two-sample FIT
decreased less than the cost-effectiveness of one-sample FIT
strategies, but one-sample FIT screening remained dominant.
Nevertheless, we need further data from repeat screening rounds
in The Netherlands to get a good estimate of systematic false-
negative rates in the population we modelled. Second, we
assumed the screening attendance rate to be independent of
screening intensity and the number of FITsamples performed. In
the first screening round of one of the Dutch trials,10e12 the
screening attendance rate was not significantly different
between the two-sample FIT and one-sample FIT study arm
(61.3% vs 61.5%; p¼0.837). However, it could be hypothesised
that, for example, adherence in the case of a more intense
screening schedule with one-sample FIT would decrease
compared with less intense screening schedules with
two-sample screening. This would negatively affect the
cost-effectiveness of more intensive screening strategies relative
to two-sample testing and might alter our conclusions. Third,
we based our analyses on a screening-naive population.
Depending on the amount of previous screening, CRC incidence
in the population and the resulting cost-effectiveness could be
lower. However, this would affect the strategies we compared in
a similar way. If anything, the effect of previous screening would
make one-sample FIT screening more preferable, because a lower
CRC incidence would reduce the added value of a second FIT
sample. Finally, we did not perform a probabilistic sensitivity
analysis. Given the large number of strategies that has to be
evaluated for each draw, such an analysis would require a huge
computational effort. We believe that simulating the range of
varying strategies is one of the strengths of this analysis, because
we were primarily interested in the comparison of different FIT
screening strategies with varying numbers of samples provided,
FIT cut-off levels, screening intervals and age ranges. Regardless
of this, data on the probability distributions of most of the
parameter values are lacking, which makes the interpretation of
a probabilistic sensitivity analysis difficult and the outcome of
limited added value. One of the most uncertain assumptions
of the model is that all CRC arise from adenoma precursors. For
FIT screening, this assumption will have limited impact because
FIT has a low sensitivity for adenomas. In addition, the
assumption of non-bleeding (and therefore for FITundetectable)
adenomas was evaluated in the sensitivity analysis by assuming
correlation between false-negative results.
In conclusion, our analysis provides new insights for decision-
makers; in a situation in which attendance to screening does not
differ between strategies, intensifying screening with one-
sample FITwas found to be more cost-effective than providing
two FIT samples within one screening round. It is therefore
recommended to increase the number of screening rounds with
one-sample FIT screening, before considering increasing the
number of FIT samples provided per screening round.
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Table 3 Costs per LYG compared with no screening and ICER of the cost-effective screening strategies, in a population with realistic attendance* at
the screening programme
Strategyy Test (cut-off) Start age (y) Stop age (y) Interval (y) LYG (y) Costs (V) Costs/LYG (V) ICERz (V)
1 1s FIT (50) 60 69 3 52 110 000 2115 2115
2 1s FIT (50) 60 70 2 67 147 000 2200 2500
3 1s FIT (50) 60 74 2 80 194 000 2420 3524
4 1s FIT (50) 55 75 2 97 261 000 2688 3956
5 1s FIT (50) 55 74.5 1.5 107 306 000 2865 4613
6 1s FIT (50) 55 79 1.5 119 377 000 3159 5678
7 1s FIT (50) 50 80 1.5 131 463 000 3541 7480
8 1s FIT (50) 55 80 1 137 522 000 3806 9427
9 1s FIT (50) 50 80 1 147 615 000 4191 9590
10 1s FIT (50) 45 80 1 151 704 000 4667 22 099
11 2s FIT $1s pos. (50) 45 80 1 153 835 000 5444 51 336
Costs and LYG are expressed per 1000 individuals aged 45 years and older in 2005.
The strategies are in ascending order from least to most costly.
The screening interventions were modelled from the year 2005, all individuals were invited for screening until they reached the end age for that particular screening strategy, and healthcare
costs for each individual were calculated until death. Costs and LYG were discounted at an annual rate of 3%.
*Attendance rate was 60% for screening, 85% for diagnostic colonoscopies, and 80% for surveillance colonoscopies.
yThe strategy number corresponds to the strategies on the efficient frontier in figure 3.
zThe ICER of an efficient strategy is determined by comparing its additional costs and effects with those of the next less costly and less effective efficient strategy.
FIT, faecal immunochemical test; ICER, incremental cost-effectiveness ratio; LYG, life-years gained.
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